ES2010226A6 - Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos - Google Patents

Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos

Info

Publication number
ES2010226A6
ES2010226A6 ES8702106A ES8702106A ES2010226A6 ES 2010226 A6 ES2010226 A6 ES 2010226A6 ES 8702106 A ES8702106 A ES 8702106A ES 8702106 A ES8702106 A ES 8702106A ES 2010226 A6 ES2010226 A6 ES 2010226A6
Authority
ES
Spain
Prior art keywords
stimulating factor
colony stimulating
granulocyte colony
factor composition
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8702106A
Other languages
English (en)
Inventor
Minoru Machida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ES2010226A6 publication Critical patent/ES2010226A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN PROCEDIMIENTO PARA PRODUCIR UNA PREPARACION FARMACEUTICA ESTABLE QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS (G-CSF). CONSISTENTE EN MEZCLAR A UNA TEMPERATURA DE 1 A 30GC EL FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS (G-CSF) CON POR LO MENOS UNA SUSTANCIA SELECCIONADA DE UN GRUPO FORMADO POR UN AGENTE TENSIOACTIVO FARMACEUTICAMENTE ACEPTABLE EN UNA CANTIDAD DE 1-10.000 PARTES EN PESO POR PARTE EN PESO DEL (G-CSF), UN SACARIDO EN UNA CANTIDAD DE 1-10.000 PARTES EN PESO POR PARTE EN PESO DEL (G-CSF), UNA PROTEINA EN CANTIDAD DE 1-20.000 PARTES EN PESO POR PARTE EN PESO DEL (G-CSF) Y UN COMPUESTO DE ALTO PESO MOLECULAR EN CABTIDAD DE 1-20.000 PARTES EN PESO POR PARTE EN PESO DEL (G-CSF); DISOLVER LA MEZCLA EN UNA SOLUCION TAMPON Y ESTERILIZAR LA SOLUCION. DICHA PREPARACION FARMACEUTICA ES UTIL PARA TRATAR INFECCIONES BACTERIANAS DADA SU CAPACIDAD DE ACTIVAR LAS FUNCIONES PROFILACTICAS DEL HUESPED O PERSONA INFECTADA.
ES8702106A 1986-07-18 1987-07-17 Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos Expired ES2010226A6 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18
JP16948986 1986-07-18

Publications (1)

Publication Number Publication Date
ES2010226A6 true ES2010226A6 (es) 1989-11-01

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8702106A Expired ES2010226A6 (es) 1986-07-18 1987-07-17 Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos

Country Status (24)

Country Link
KR (1) KR930004597B1 (es)
CN (1) CN1033738C (es)
AT (1) AT402259B (es)
AU (1) AU611856B2 (es)
BE (1) BE1000253A3 (es)
CA (1) CA1297007C (es)
CH (1) CH671157A5 (es)
DE (1) DE3723781C2 (es)
DK (1) DK171308B1 (es)
ES (1) ES2010226A6 (es)
FR (1) FR2601591B1 (es)
GB (1) GB2193631B (es)
GR (1) GR871067B (es)
HK (1) HK64893A (es)
HU (1) HU198627B (es)
IE (1) IE60290B1 (es)
IL (1) IL83220A (es)
IT (1) IT1218927B (es)
NL (1) NL192917C (es)
NO (1) NO171828C (es)
PT (1) PT85343B (es)
SE (1) SE503312C2 (es)
SG (1) SG64393G (es)
YU (1) YU47543B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
DE60103940T2 (de) * 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1329224A4 (en) 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
BR112012017979B1 (pt) * 2010-01-19 2021-10-13 Hanmi Science Co., Ltd. Formulações líquidas para conjugado de g-csf de ação prolongada
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
SE451844B (sv) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
EP0211899B1 (en) * 1985-02-05 1992-09-23 Cetus Oncology Corporation Purification of native colony stimulating factor-1
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
DK368387A (da) 1988-01-19
NL8701640A (nl) 1988-02-16
SE8702907D0 (sv) 1987-07-17
IT1218927B (it) 1990-04-24
GB8716904D0 (en) 1987-08-26
FR2601591B1 (fr) 1991-04-26
DK368387D0 (da) 1987-07-15
SG64393G (en) 1993-08-06
DE3723781C2 (de) 1999-09-02
AT402259B (de) 1997-03-25
HUT44941A (en) 1988-05-30
YU134287A (en) 1989-06-30
NL192917B (nl) 1998-01-05
NO872966L (no) 1988-01-19
GB2193631A (en) 1988-02-17
KR880001297A (ko) 1988-04-22
YU47543B (sh) 1995-10-03
AU7566587A (en) 1988-01-21
IT8767594A0 (it) 1987-07-10
DK171308B1 (da) 1996-09-02
NO872966D0 (no) 1987-07-16
FR2601591A1 (fr) 1988-01-22
SE503312C2 (sv) 1996-05-13
PT85343B (pt) 1990-04-30
CA1297007C (en) 1992-03-10
DE3723781A1 (de) 1988-01-21
CH671157A5 (de) 1989-08-15
IE60290B1 (en) 1994-06-29
NO171828B (no) 1993-02-01
NO171828C (no) 1993-05-12
NL192917C (nl) 1998-05-07
CN1033738C (zh) 1997-01-08
CN87104963A (zh) 1988-02-24
GB2193631B (en) 1990-11-21
ATA177587A (de) 1996-08-15
AU611856B2 (en) 1991-06-27
HU198627B (en) 1989-11-28
HK64893A (en) 1993-07-16
IL83220A0 (en) 1987-12-31
GR871067B (en) 1987-11-19
PT85343A (en) 1987-08-01
SE8702907L (sv) 1988-01-19
KR930004597B1 (ko) 1993-06-01
IE871933L (en) 1988-01-18
BE1000253A3 (fr) 1988-09-27
IL83220A (en) 1993-01-31

Similar Documents

Publication Publication Date Title
ES2010226A6 (es) Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos
GB2200109B (en) New pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
IL84855A0 (en) Hydrosols of pharmacologically active agents,their preparation and pharmaceutical compositions containing them
HUT41221A (en) Insecticide and acaricide compositions further process for preparing phenoxy-alkyl-amino-pyridine derivatives as active ingredients thereof
IL91126A0 (en) Substituted aminomethyl-tetralins and their heterocyclic analogues,their preparation and pharmaceutical compositions containing them
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
IE852593L (en) Compositions containing anthracycline glycosides
IL92533A0 (en) Imidazoles,their preparation and pharmaceutical compositions containing them
EG18379A (en) Novel pharmacological compounds
NZ223043A (en) Sialic acid derivatives; use as stabilisers for physiologically active substances and as binders in chromatography
DE2966411D1 (en) Imidazolylvinylethers, their preparation and application as active agent in pharmaceutical and biocidal compositions
HUT39568A (en) Insecticide and acaricide compositions containing 13beta-alkyl-milbemycin derivatives as active ingredients further process for preparing the active substances
IL84554A0 (en) Imidazole derivatives,their preparation and pharmaceutical compositions containing them
DE3477924D1 (en) Benzenesulphonyl lactams, process for their preparation and their use as active ingredients in pharmaceutical compounds
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
HUT39957A (en) Insecticide and acaricide compositions and process for preparing the active ingredients
DE3068074D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
DE3070184D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
DE3067790D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
ZA894422B (en) Pyrrole derivatives,their preparation and their use as pharmaceutical active compounds
IL85651A0 (en) Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them
EP0435186A3 (en) Pyridyloxypyrimidine derivatives, preparation process thereof, and herbicidal compositions containing the same as active ingredients
IL92441A (en) Imidazole containing peptides, their preparation and pharmaceutical compositions containing them
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
EP0419157A3 (en) Pharmacologically active compound., preparation and use

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070718